The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account